In 2015, edaravone was approved as RADICUT ® for the treatment of ALS in Japan and South Korea. Marketing authorizations were subsequently granted in Canada (October 2018), Switzerland (January ...

Currently approved ALS treatments include Sanofi’s Rilutek (riluzole) and Mitsubishi Tanabe’s Radicava/Radicut (edaravone). Radicava is intended to slow the progression of ALS by preventing ...

Neuvivo has submitted a New Drug Application (NDA) for its investigational amyotrophic lateral sclerosis (ALS) immunotherapy to the US Food and Drug Administration (FDA). Neuvivo hopes its ...